EU approves AVEO’s Fotivda (tivozanib) for advanced renal cell carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The European Commission has approved AVEO Oncology’s Fotivda (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma in the European Union plus Norway and Iceland.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login